 |
14 Diseases |  |
3 Trials |
|
3 Trials |  |
139 News |  |
| «123 |
- Artlegia (olokizumab) - R / Pharm
Enrollment change: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease (clinicaltrials.gov) - Oct 28, 2012
P2, N=0, Withdrawn, Sponsor: UCB BIOSCIENCES GmbH
N=96 --> 0
- |||| Artlegia (olokizumab) - R / Pharm
Trial completion: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy (clinicaltrials.gov) - Jul 25, 2012
P2, N=221, Completed, Sponsor: UCB, Inc.
N=96 --> 0 Active, not recruiting --> Completed
- Artlegia (olokizumab) - R / Pharm
New P2 trial: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease (clinicaltrials.gov) - Jul 5, 2012
P2, N=0, Withdrawn, Sponsor: UCB BIOSCIENCES GmbH
- ||||| Artlegia (olokizumab) - R / Pharm
New P2 trial: The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 13, 2012
P2, N=103, Completed, Sponsor: UCB, Inc.
- ||||| Artlegia (olokizumab) - R / Pharm
New P2 trial: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy (clinicaltrials.gov) - Oct 30, 2011
P2, N=119, Completed, Sponsor: UCB Japan Co. Ltd.
- Artlegia (olokizumab) - R / Pharm
Enrollment change, IO biomarker: Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects (clinicaltrials.gov) - Sep 25, 2011
P1, N=20, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed N=40 --> 20
- | Artlegia (olokizumab) - R / Pharm
Trial completion, IO biomarker: Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects (clinicaltrials.gov) - Sep 25, 2011
P1, N=20, Completed, Sponsor: UCB, Inc.
N=40 --> 20 Recruiting --> Completed